Tags

Type your tag names separated by a space and hit enter

Fibroblast growth factor 23 and the heart.
Curr Opin Nephrol Hypertens. 2012 Jul; 21(4):369-75.CO

Abstract

PURPOSE OF REVIEW

Elevated serum levels of the phosphaturic hormone fibroblast growth factor 23 (FGF23) are strongly associated with chronic kidney disease (CKD) progression and mortality, and are also independently associated with left ventricular hypertrophy, a major contributor to cardiovascular disease (CVD) and death in CKD patients. As FGF23 levels rise long before serum phosphate in CKD, FGF23 is a more sensitive biomarker of disordered phosphate metabolism and its associated renal and CVD toxicity.

RECENT FINDINGS

This review will address the novel possibility that FGF23 contributes directly to CVD in patients with CKD. We will summarize the basic principles of FGF-mediated signal transduction and review the current literature on effects of FGF family members on the heart as well as FGF23 signaling in 'classic' target cells, in order to flesh out the novelty underlying FGF23-induced cell signaling in the heart. By doing so we will speculate on why such a direct cardiac effect has not been described before, and suggest a novel target for pharmacological intervention.

SUMMARY

By demonstrating direct pathological effects of FGF23 on the heart, novel findings from a recent translational study reposition FGF23 from biomarker of risk, to mechanism of disease. Therefore the pharmacological interference with FGF23 and/or its cardiac receptor in CKD patients could be beneficial to prevent or treat CVD.

Authors+Show Affiliations

Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida 33136, USA. cfaul@med.miami.edu

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

22531163

Citation

Faul, Christian. "Fibroblast Growth Factor 23 and the Heart." Current Opinion in Nephrology and Hypertension, vol. 21, no. 4, 2012, pp. 369-75.
Faul C. Fibroblast growth factor 23 and the heart. Curr Opin Nephrol Hypertens. 2012;21(4):369-75.
Faul, C. (2012). Fibroblast growth factor 23 and the heart. Current Opinion in Nephrology and Hypertension, 21(4), 369-75. https://doi.org/10.1097/MNH.0b013e32835422c4
Faul C. Fibroblast Growth Factor 23 and the Heart. Curr Opin Nephrol Hypertens. 2012;21(4):369-75. PubMed PMID: 22531163.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fibroblast growth factor 23 and the heart. A1 - Faul,Christian, PY - 2012/4/26/entrez PY - 2012/4/26/pubmed PY - 2012/10/4/medline SP - 369 EP - 75 JF - Current opinion in nephrology and hypertension JO - Curr Opin Nephrol Hypertens VL - 21 IS - 4 N2 - PURPOSE OF REVIEW: Elevated serum levels of the phosphaturic hormone fibroblast growth factor 23 (FGF23) are strongly associated with chronic kidney disease (CKD) progression and mortality, and are also independently associated with left ventricular hypertrophy, a major contributor to cardiovascular disease (CVD) and death in CKD patients. As FGF23 levels rise long before serum phosphate in CKD, FGF23 is a more sensitive biomarker of disordered phosphate metabolism and its associated renal and CVD toxicity. RECENT FINDINGS: This review will address the novel possibility that FGF23 contributes directly to CVD in patients with CKD. We will summarize the basic principles of FGF-mediated signal transduction and review the current literature on effects of FGF family members on the heart as well as FGF23 signaling in 'classic' target cells, in order to flesh out the novelty underlying FGF23-induced cell signaling in the heart. By doing so we will speculate on why such a direct cardiac effect has not been described before, and suggest a novel target for pharmacological intervention. SUMMARY: By demonstrating direct pathological effects of FGF23 on the heart, novel findings from a recent translational study reposition FGF23 from biomarker of risk, to mechanism of disease. Therefore the pharmacological interference with FGF23 and/or its cardiac receptor in CKD patients could be beneficial to prevent or treat CVD. SN - 1473-6543 UR - https://www.unboundmedicine.com/medline/citation/22531163/Fibroblast_growth_factor_23_and_the_heart_ L2 - https://doi.org/10.1097/MNH.0b013e32835422c4 DB - PRIME DP - Unbound Medicine ER -